GlassScriptPhysician profile
Nicole Massie
NPI 1033182241
$8,003.85
in general payments reported to CMS, 2019-2025
27 companies · $571 in 2025
The $571 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
See the full distribution for Urogynecology and Reconstructive Pelvic Surgery (Urology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $536 · 2021: $1,163 · 2022: $987 · 2023: $3,300 · 2024: $737 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Travel and Lodging: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.62 |
| Travel and Lodging | $1,801.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,697.10 | 2020-2024 | Axonics, Bulkamid |
| Abbvie INC. | $868.04 | 2022-2025 | |
| Allergan, INC. | $696.90 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $480.51 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $398.65 | 2019-2024 | Myrbetriq, Veozah |
| Caldera Medical, INC | $369.78 | 2021 | |
| Coloplast Corp | $280.95 | 2019-2023 | Saffron |
| Medtronic, INC. | $206.37 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $174.21 | 2020 | |
| Rochester Medical Corporation | $141.91 | 2021 | |
| Urovant Sciences INC | $125.94 | 2021-2022 | |
| Therapeuticsmd, INC. | $122.00 | 2019 | |
| Boston Scientific Corporation | $75.69 | 2021-2025 | Axonics |
| Pfizer INC. | $61.12 | 2019-2025 | |
| Procept Biorobotics Corporation | $50.24 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $38.17 | 2019-2022 | |
| Antares Pharma, INC. | $35.49 | 2024 | Xyosted |
| Endo Pharmaceuticals INC. | $27.78 | 2023-2024 | Xiaflex |
| Conmed Corporation | $25.08 | 2020 | |
| Endo USA, INC. | $23.82 | 2025 | Xiaflex |
| Convatec INC. | $20.64 | 2019 | |
| Blue Earth Diagnostics | $20.16 | 2023 | |
| Dendreon Pharmaceuticals LLC | $18.29 | 2019 | |
| Abbott Laboratories | $16.76 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.67 | 2019 | |
| Duchesnay USA Incorporated | $12.27 | 2019 | |
| Travere Therapeutics, INC. | $1.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Massie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.